Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan
Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination. This single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had rec...
Saved in:
Published in | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 27; no. 12; pp. 1713 - 1715 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Ltd
01.12.2021
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination.
This single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had received two doses of COVID-19 vaccination (BNT162b2) 21 days apart. We measured serum immunoglobulin G (IgG) to nucleoprotein and spike protein of SARS-CoV-2 with commercially available kits before and 7, 14, and 35 days after the first dose of vaccination.
A total of 104 workers participated in this study. Of these, 7 participants were seropositive with antibodies to spike protein at baseline and 4 of the 7 seropositive participants had COVID-19 history. The mean level of IgG to spike protein (QT) was 45.2, 1219, 2845, and 23489 AU/mL at baseline, on days 7, 14, and 35, respectively, although the values for nucleoprotein (NG) were 0.2, 0.21, 0.22, and 0.19 S/C, respectively. On day 7, QT in seropositive participants at baseline was elevated, whereas it was not elevated in seronegative participants at baseline until day 14.
QT was elevated over the cutoff in all the participants at day 35, but NG did not change between baseline and day 35. |
---|---|
AbstractList | Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination.BACKGROUNDVaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination.This single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had received two doses of COVID-19 vaccination (BNT162b2) 21 days apart. We measured serum immunoglobulin G (IgG) to nucleoprotein and spike protein of SARS-CoV-2 with commercially available kits before and 7, 14, and 35 days after the first dose of vaccination.METHODSThis single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had received two doses of COVID-19 vaccination (BNT162b2) 21 days apart. We measured serum immunoglobulin G (IgG) to nucleoprotein and spike protein of SARS-CoV-2 with commercially available kits before and 7, 14, and 35 days after the first dose of vaccination.A total of 104 workers participated in this study. Of these, 7 participants were seropositive with antibodies to spike protein at baseline and 4 of the 7 seropositive participants had COVID-19 history. The mean level of IgG to spike protein (QT) was 45.2, 1219, 2845, and 23489 AU/mL at baseline, on days 7, 14, and 35, respectively, although the values for nucleoprotein (NG) were 0.2, 0.21, 0.22, and 0.19 S/C, respectively. On day 7, QT in seropositive participants at baseline was elevated, whereas it was not elevated in seronegative participants at baseline until day 14.RESULTSA total of 104 workers participated in this study. Of these, 7 participants were seropositive with antibodies to spike protein at baseline and 4 of the 7 seropositive participants had COVID-19 history. The mean level of IgG to spike protein (QT) was 45.2, 1219, 2845, and 23489 AU/mL at baseline, on days 7, 14, and 35, respectively, although the values for nucleoprotein (NG) were 0.2, 0.21, 0.22, and 0.19 S/C, respectively. On day 7, QT in seropositive participants at baseline was elevated, whereas it was not elevated in seronegative participants at baseline until day 14.QT was elevated over the cutoff in all the participants at day 35, but NG did not change between baseline and day 35.CONCLUSIONSQT was elevated over the cutoff in all the participants at day 35, but NG did not change between baseline and day 35. Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination. This single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had received two doses of COVID-19 vaccination (BNT162b2) 21 days apart. We measured serum immunoglobulin G (IgG) to nucleoprotein and spike protein of SARS-CoV-2 with commercially available kits before and 7, 14, and 35 days after the first dose of vaccination. A total of 104 workers participated in this study. Of these, 7 participants were seropositive with antibodies to spike protein at baseline and 4 of the 7 seropositive participants had COVID-19 history. The mean level of IgG to spike protein (QT) was 45.2, 1219, 2845, and 23489 AU/mL at baseline, on days 7, 14, and 35, respectively, although the values for nucleoprotein (NG) were 0.2, 0.21, 0.22, and 0.19 S/C, respectively. On day 7, QT in seropositive participants at baseline was elevated, whereas it was not elevated in seronegative participants at baseline until day 14. QT was elevated over the cutoff in all the participants at day 35, but NG did not change between baseline and day 35. |
Author | Tachikawa, Natsuo Miyazaki, Kazuhito Sasaki, Hiroaki Miyata, Nobuyuki Yoshimura, Yukihiro |
Author_xml | – sequence: 1 givenname: Yukihiro surname: Yoshimura fullname: Yoshimura, Yukihiro email: yu10-yoshimura@city.yokohama.jp – sequence: 2 givenname: Hiroaki surname: Sasaki fullname: Sasaki, Hiroaki – sequence: 3 givenname: Nobuyuki surname: Miyata fullname: Miyata, Nobuyuki – sequence: 4 givenname: Kazuhito orcidid: 0000-0002-0079-2883 surname: Miyazaki fullname: Miyazaki, Kazuhito – sequence: 5 givenname: Natsuo surname: Tachikawa fullname: Tachikawa, Natsuo |
BookMark | eNqFkUtrFEEQxxuJmId-AU999DKTfsyjR0SIq-ZBMAhRvDU1NTVub2a71-7ZDfvtnWWDYA7JqQqqfv96_I_ZgQ-eGHsrRS6FrE4X-cIB5koomQuTC2FesCNZ6DqrayMOplwXMtNK_jpkxykthJB1acwrdqiLQqrG6CP2_cyPrg3dlkdKq-ATcehHinx28_PycyYbvgFE54l_-nYrK9UqHjyfEwzjnCNE4vch3lFM3Hl-BSvwr9nLHoZEbx7iCfvx9cvt7CK7vjm_nJ1dZ1iKesxAd0VvJCKqrjBQCD3dUWOPCI1C0UEHpdaSQFTYtWSgRoFC6baCthdVqU_Yx73uat0uqUPyY4TBrqJbQtzaAM7-X_Fubn-HjTW6NKJpJoF3DwIx_FlTGu3SJaRhAE9hnawqK10obZSeWtW-FWNIKVL_b4wUdueFXdidF3bnhRXGTl5MkHkEoRthdGG3jhueRj_sUZoeuHEUbUJHHqlzkXC0XXBP4-8f4Tg47xCGO9o-B_8Fq5O5GA |
CitedBy_id | crossref_primary_10_3390_vaccines11010051 crossref_primary_10_29328_journal_icci_1001020 crossref_primary_10_1007_s15010_022_01779_x crossref_primary_10_1016_j_ijid_2022_04_057 crossref_primary_10_1080_14760584_2022_2093722 crossref_primary_10_5937_jomb0_33999 |
Cites_doi | 10.1038/s41586-020-2639-4 10.1016/S0140-6736(21)00501-8 10.1056/NEJMc2101667 10.1128/JCM.00388-21 10.1038/s41591-021-01325-6 10.1128/JCM.00941-20 10.1056/NEJMoa2034577 10.1001/jamainternmed.2020.4616 |
ContentType | Journal Article |
Copyright | 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases |
Copyright_xml | – notice: 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases – notice: Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. – notice: 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases |
DBID | AAYXX CITATION 7X8 5PM |
DOI | 10.1016/j.jiac.2021.08.008 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1437-7780 |
EndPage | 1715 |
ExternalDocumentID | PMC8358099 10_1016_j_jiac_2021_08_008 S1341321X21002208 |
GroupedDBID | --- --M -Y2 -~C .1- .55 .86 .FO .~1 0R~ 0VY 1N0 1P~ 1SB 1~. 2.D 28- 29K 2JY 2P1 2VQ 2~H 30V 4.4 408 409 40D 457 4G. 53G 5GY 5QI 5VS 67Z 6NX 7-5 8P~ 8TC 8UJ 95. 95~ AAAJQ AAEDT AAEDW AAIAL AAIKJ AAKOC AALRI AANXM AAOAW AAQFI AARHV AATTM AAXKI AAXUO AAYWO AAYZH ABFSG ABJNI ABMAC ABMNI ABMZM ABQSL ABXDB ACDAQ ACGFS ACIEU ACOMO ACRLP ACSTC ACVFH ADBBV ADCNI ADEZE ADHKG ADIMF ADKPE ADQRH ADRFC ADVLN AEBSH AEFIE AEIPS AEKER AENEX AEUPX AEVXI AEZWR AFBBN AFEXP AFHIU AFLOW AFPUW AFRHN AFTJW AFWTZ AFXIZ AGCQF AGGDS AGHFR AGJBK AGQPQ AGUBO AHBYD AHKAY AHSBF AHWEU AIEXJ AIGII AIIUN AIKHN AITUG AIXLP AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BA0 BBWZM BGNMA BKOJK BLXMC BNPGV CAG CJTIS COF CS3 CSCUP D-I DL5 EBS EFJIC EFKBS EJD EMOBN EN4 F5P FDB FEDTE FIRID FYGXN GBLVA GQ8 GXS H13 HF~ HG5 HG6 HMJXF HVGLF HZ~ I09 IHE IXC IXE IZIGR IZQ I~X KDC KOM KOW KPH LAS M41 M4Y MA- MO0 N2Q N9A NB0 NDZJH NU0 O9- O93 O9G O9I OAM OAUVE OC~ P-8 P-9 P19 P2P P9S PC. PT5 QOK QOS R4E R89 R9I RNI ROL RPX RRX RSV RZK S1Z S26 S27 S28 S37 S3B SDE SDH SDM SMD SOJ SPCBC SSH SSZ SV3 T13 T16 T5K TSK TSV TT1 TUC U2A VC2 WJK WK8 X7M Z45 Z5R ~A9 ~EX ~G- -5E -5G -BR 0SF AACTN AAIAV ABLVK ABTEG ABYKQ ADINQ AFKWA AFNRJ AHPSJ AJBFU AJOXV AMFUW EFLBG GQ6 NCXOZ RIG SSI SZN Z7U Z82 Z87 Z8O Z8V Z91 AAYXX AFCTW AGRNS CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c507t-a3d4f81ccc2d48a4032027cfcca92c0dada5331ea06cdbe8a7c0c023b6abf0653 |
IEDL.DBID | .~1 |
ISSN | 1341-321X 1437-7780 |
IngestDate | Thu Aug 21 18:21:00 EDT 2025 Thu Jul 10 17:51:24 EDT 2025 Thu Apr 24 23:01:51 EDT 2025 Tue Jul 01 02:23:37 EDT 2025 Fri Feb 23 02:43:23 EST 2024 Tue Aug 26 18:43:08 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | COVID-19 Antibody Vaccination Health care worker Japan |
Language | English |
License | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c507t-a3d4f81ccc2d48a4032027cfcca92c0dada5331ea06cdbe8a7c0c023b6abf0653 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-0079-2883 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8358099 |
PMID | 34412983 |
PQID | 2563423823 |
PQPubID | 23479 |
PageCount | 3 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8358099 proquest_miscellaneous_2563423823 crossref_primary_10_1016_j_jiac_2021_08_008 crossref_citationtrail_10_1016_j_jiac_2021_08_008 elsevier_sciencedirect_doi_10_1016_j_jiac_2021_08_008 elsevier_clinicalkey_doi_10_1016_j_jiac_2021_08_008 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-12-01 |
PublicationDateYYYYMMDD | 2021-12-01 |
PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
PublicationYear | 2021 |
Publisher | Elsevier Ltd Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd – name: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
References | Bryan, Pepper, Wener, Fink, Morishima, Chaudhary (bib4) 2020; 58 Narasimhan, Mahimainathan, Araj, Clark, Markantonis, Green (bib5) 2021 Wu, Liu, Wang, Lu, Wang, Gu (bib9) 2020; 180 World Health Organization (bib2) Krammer, Srivastava, Alshammary, Amoako, Awawda, Beach (bib11) 2021; 384 World Health Organization (bib1) Manisty, Otter, Treibel, McKnight, Altmann, Brooks (bib7) 2021; 397 Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart (bib6) 2020; 383 bib10 Mulligan, Lyke, Kitchin, Absalon, Gurtman, Lockhart (bib3) 2020; 586 Ebinger, Fert-Bober, Printsev, Wu, Sun, Prostko (bib8) 2021 Polack (10.1016/j.jiac.2021.08.008_bib6) 2020; 383 Ebinger (10.1016/j.jiac.2021.08.008_bib8) 2021 Manisty (10.1016/j.jiac.2021.08.008_bib7) 2021; 397 Wu (10.1016/j.jiac.2021.08.008_bib9) 2020; 180 Krammer (10.1016/j.jiac.2021.08.008_bib11) 2021; 384 World Health Organization (10.1016/j.jiac.2021.08.008_bib2) World Health Organization (10.1016/j.jiac.2021.08.008_bib1) Mulligan (10.1016/j.jiac.2021.08.008_bib3) 2020; 586 Bryan (10.1016/j.jiac.2021.08.008_bib4) 2020; 58 Narasimhan (10.1016/j.jiac.2021.08.008_bib5) 2021 |
References_xml | – year: 2021 ident: bib5 article-title: Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups publication-title: J Clin Microbiol – ident: bib1 article-title: WHO coronavirus (COVID-19) dashboard – volume: 58 start-page: 20 year: 2020 ident: bib4 article-title: Performance characteristics of the abbott architect SARS-CoV-2 IgG assay and seroprevalence in boise, Idaho publication-title: J Clin Microbiol – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: bib6 article-title: Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine publication-title: N Engl J Med – volume: 180 start-page: 1356 year: 2020 end-page: 1362 ident: bib9 article-title: Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in shanghai, China publication-title: JAMA Intern Med – ident: bib10 – volume: 384 start-page: 1372 year: 2021 end-page: 1374 ident: bib11 article-title: Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine publication-title: N Engl J Med – year: 2021 ident: bib8 article-title: Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 publication-title: Nat Med – volume: 586 start-page: 589 year: 2020 end-page: 593 ident: bib3 article-title: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults publication-title: Nature – volume: 397 start-page: 1057 year: 2021 end-page: 1058 ident: bib7 article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals publication-title: Lancet – ident: bib2 article-title: COVID-19 vaccines – ident: 10.1016/j.jiac.2021.08.008_bib1 – volume: 586 start-page: 589 year: 2020 ident: 10.1016/j.jiac.2021.08.008_bib3 article-title: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults publication-title: Nature doi: 10.1038/s41586-020-2639-4 – volume: 397 start-page: 1057 year: 2021 ident: 10.1016/j.jiac.2021.08.008_bib7 article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals publication-title: Lancet doi: 10.1016/S0140-6736(21)00501-8 – volume: 384 start-page: 1372 year: 2021 ident: 10.1016/j.jiac.2021.08.008_bib11 article-title: Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine publication-title: N Engl J Med doi: 10.1056/NEJMc2101667 – year: 2021 ident: 10.1016/j.jiac.2021.08.008_bib5 article-title: Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups publication-title: J Clin Microbiol doi: 10.1128/JCM.00388-21 – year: 2021 ident: 10.1016/j.jiac.2021.08.008_bib8 article-title: Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 publication-title: Nat Med doi: 10.1038/s41591-021-01325-6 – ident: 10.1016/j.jiac.2021.08.008_bib2 – volume: 58 start-page: 20 year: 2020 ident: 10.1016/j.jiac.2021.08.008_bib4 article-title: Performance characteristics of the abbott architect SARS-CoV-2 IgG assay and seroprevalence in boise, Idaho publication-title: J Clin Microbiol doi: 10.1128/JCM.00941-20 – volume: 383 start-page: 2603 year: 2020 ident: 10.1016/j.jiac.2021.08.008_bib6 article-title: Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 – volume: 180 start-page: 1356 year: 2020 ident: 10.1016/j.jiac.2021.08.008_bib9 article-title: Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in shanghai, China publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2020.4616 |
SSID | ssj0017588 |
Score | 2.31507 |
Snippet | Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after... |
SourceID | pubmedcentral proquest crossref elsevier |
SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 1713 |
SubjectTerms | Antibody COVID-19 Health care worker Japan Original Vaccination |
Title | Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1341321X21002208 https://dx.doi.org/10.1016/j.jiac.2021.08.008 https://www.proquest.com/docview/2563423823 https://pubmed.ncbi.nlm.nih.gov/PMC8358099 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEA_ivfgi6il-E-HwRes2abZNH_f2lFVxVVxl30K-ihXJiq7Cvvi3X6ZpVxcOD3xsm4EkM5kZmt_8BqFfGTVFoayNDCFFxHzKHCnL4G8TSdrGJBmVUO980U97t-xs2B7OoW5TCwOwytr3B59eeev6TavezdZTWbZugIosoWRIgUWUVgW_jGVg5UfvU5iHj45V70kYHMHounAmYLweSgk0hjTQeEKLyX8Hp0_J5yx08lMsOllCi3USiTthnstozroVtH8VWKgnh3jwUVT1coj38dUHP_XkJ7ruuHGpRmaCnwNA1uKqUzjuXt6d_olIjt-khvt2_Ls_IClVFI8cDgWTGJBiGMBcPm3EpcNnPti6VXR7cjzo9qK6s0Kkff43jmRiWMGJ1poaxiWruqhnuvDqzKmOjTTSp4HEyjjVRlkuMx1rH91VKlUBbLZraN6NnF1HuOA2lzFRwNPGuLF5apOY6ZhnkqaWJBuINFsqdE07Dt0vHkWDL3sQoAYBahDQEjPmG-hgKvMUSDe-HJ00mhJNOal3gMLHhC-l2lOpGYP7r9xeYwzCn0S4XpHOjl5fhE8egU6RU7_mbMZKposALu_ZL668rzi9OVxH5_nmN2e1hRbgKeBsttH8-PnV7vhsaax2q-Owi350Ts97_b8JDBUE |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOcAF8RTlaSTohYaNHW_iHHooLdVuH0sRW7Q316-IVChbdbet9tI_xR9kJk62XQkVCanXJBPZM_bMJP7mG0LeZ9wVhfE-cowVkYCUOTJe4N8mlnSdSzKusd55f5D2DsXOqDtaIr_bWhiEVTa-P_j02ls3VzqNNjsnZdn5jlRkCWcjjiyiPJYNsnLXzy7gu22y3t8CI3_gfPvLcLMXNa0FIgsJ0DTSiROFZNZa7oTUom4jntkC5pNzGzvtNORBzOs4tc54qTMbWwhvJtWmQDpXeO8dcleAu8C2CZ8u57gSCMd1s0scXYTDayp1AqjsuNTIm8gDbyj2tPx7NLyW7S5iNa8Fv-2H5EGTtdKNoJhHZMlXj8nqQaC9nq3R4VUV12SNrtKDK0Ls2RPybaOalmbsZvQ0IHI9rVuT082vP_pbEcvpubZ4wE8_D4Ys5YbTcUVDhSZFaBpF9BjkqbSs6A5E9-opObwVfT8jy9W48s8JLaTPdcwMEsMJ6Xye-iQWNpaZ5qlnyQphrUqVbXjOsd3GL9UC2o4VmkGhGRT24IzlCvk4lzkJLB83Pp20llJt_Sp4XAVB6Eap7lxqYYX_U-5duxgUbH08z9GVH59NFGSryN8oOcw5W1gl80kgefjinar8WZOISzz_zvMX_zmqt-Reb7i_p_b6g92X5D7eCSCfV2R5enrmX0OqNjVv6q1BydFt78U_9Q1SnA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibody+response+after+COVID-19+vaccine+BNT162b2+on+health+care+workers+in+Japan&rft.jtitle=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.au=Yoshimura%2C+Yukihiro&rft.au=Sasaki%2C+Hiroaki&rft.au=Miyata%2C+Nobuyuki&rft.au=Miyazaki%2C+Kazuhito&rft.date=2021-12-01&rft.pub=Elsevier+Ltd&rft.issn=1341-321X&rft.volume=27&rft.issue=12&rft.spage=1713&rft.epage=1715&rft_id=info:doi/10.1016%2Fj.jiac.2021.08.008&rft.externalDocID=S1341321X21002208 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-321X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-321X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-321X&client=summon |